Value of combined morphologic, cytochemical, and immunophenotypic features in predicting recurrent cytogenetic abnormalities in acute myeloid leukemia

Human Pathology

Volumn 34, Issue 5, 2003, Pages 479-483

  Arber, Daniel A ^a   Carter, Nora H ^b   Ikle, David ^b   Slovak, Marilyn L ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Acute myeloid leukemia; Classification; Cytochemistry; Cytogenetics; Immunophenotype; Morphology

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER RECURRENCE; CHILD; CHROMOSOME 11Q; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 16; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CLINICAL FEATURE; CYTOCHEMISTRY; CYTOGENETICS; DIAGNOSTIC VALUE; EVALUATION; FEMALE; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; PREDICTION; RELIABILITY; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

EID: 0038620329     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(03)00085-6     Document Type: Article

References (27)

1. Bennett JM, Catovsky D, Daniel M-T, et al: Proposals for the classification of the acute leukemias. Br J Haematol 33:451-458, 1976
2. Bennett JM, Catovsky D, Daniel MT, et al: Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103:626-629, 1985
3. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
4. Jaffe ES, Harris NL, Stein H, et al (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001
5. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92:2322-2333, 1998
6. Raimondi SC, Chang MN, Ravindranath Y, et al: Chromosomal abnormalities in 478 children with acute myeloid leukemia: Clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group study - POG 8821. Blood 94:3707-3716, 1999
7. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96:4075-4083, 2000
8. Grimwade D, Walker H, Harrison G, et al: The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98:1312-1320, 2001
9. Paietta E, Andersen J, Gallagher R, et al: The immunophenotype of acute promyelocytic leukemia (APL): An ECOG study. Leukemia 8:1108-1112, 1994
10. Guglielmi C, Martelli MP, Diverio D, et al: Immunophenotype of adult and childhood acute promyelocytic leukaemia: Correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol 102:1035-1041, 1998
11. Kita K, Nakase K, Miwa H, et al: Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: Frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 80:470-477, 1992
12. Nakamura H, Kuriyama K, Sadamori N, et al: Morphological subtyping of acute myeloid leukemia with maturation (AML-M2): Homogeneous pink-colored cytoplasm of mature neutrophils is most characteristic and AML-M2 with t(8;21). Leukemia 11:651-655; 1997.
13. Hurwitz CA, Raimondi SC, Head D, et al: Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood 80:3182-3188, 1992
14. Adriaansen HJ, te Boekhorst PAW, Hagemeijer AM, et al: Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16) (p13q22) exhibits a specific immunophenotype with CD2 expression. Blood 81:3043-3051, 1993
15. Paietta E, Wiernik PH, Andersen J, et al: Acute myeloid leukemia M4 with inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression. Blood 82:2595, 1993
16. Arber DA: Realistic pathologic classification of acute myeloid leukemias. Am J Clin Pathol 115:552-560, 2001
17. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
18. Pearson K: In the chi-square test of goodness of fit. Biometrika 9:22-27, 1922
19. Arber DA, Stein AS, Carter NH, et al: Prognostic impact of acute myeloid leukemia classification: Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. Am J Clin Pathol 2003 (in press).
20. Tallman MS, Andersen JW, Schiffer CA, et al: All-transretinoic acid in acute promyelocytic leukemia. N Engl J Med 337: 1021-1028, 1997
21. Lo Coco F, Nervi C, Avvisati G, et al: Review and meeting report. Acute promyelocytic leukemia: A curable disease. Leukemia 12:-1880, 1998 1866
22. Downing JR, Higuchi M, Lenny N, et al: Alterations of the AML1 transcription factor in human leukemia. Semin Cell Dev Biol 11:347-360, 2000
23. Hilden JM, Smith FO, Frestedt JL, et al: MLL gene rearrangement, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia. Blood 89:3801-3805, 1997
24. Ghaddar HM, Plunkett W, Kantarjian HM, et al: Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia 8:1269-1274, 1994
25. Bloomfield CD, Lawrence D, Byrd JC, et al: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173-4179, 1998
26. Byrd JC, Dodge RK, Carroll A, et al: Patients with t(8; 21) (q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17:3767-3775, 1999
27. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302